Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease (CROSBI ID 98679)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Turk, Zdenka ; Šesto, Mihajlo ; Skodlar, Jasna ; Ferenčak, Goran ; Turk, Nikša ; Stavljenić-Rukavina Ana Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease // Hormone and Metabolic Research, 34 (2002), 4; 196-201-x

Podaci o odgovornosti

Turk, Zdenka ; Šesto, Mihajlo ; Skodlar, Jasna ; Ferenčak, Goran ; Turk, Nikša ; Stavljenić-Rukavina Ana

engleski

Soluble LDL-Immune Complexes in Type 2 Diabetes and Vascular Disease

Background and Aims: The oxidative modification of LDL has been shown to affect its clearance and to exert cytotoxic and immunogenic effects. The objective of our study was to analyse markers of LDL oxidation - soluble LDL containing immune complexes (LDL-ICs) in type 2 diabetes with micro- and macrovascular disease. Patients and Methods: The study included 69 diabetic patients with coronary artery disease (DM + CAD), 78 non-diabetics with CAD, 47 controls, and 27 diabetics with nephropathy and 36 free from complications. OxLDL antibodies and advanced glycated end-products were measured by ELISA, and LDL-IC apo B content after PEG precipitation. Results: Determination of a broad range of oxLDL antibody activity in all study groups showed no significant differences. In contrast, the content of apo B, a component of the antigen moiety of oxLDL-ICs, was higher in CAD and diabetes (+ CAD) than in LDL-ICs isolated from controls (p < 0.001). LDL-ICs did not differ between patients with CAD + DM and CAD patients free from diabetes. LDL-IC levels in diabetic patients with or without microangiopathy were significantly higher than in healthy volunteers (PEG-apo B 0.278 +/- 0.107 vs. 0.165 +/- 105 g/l, p < 0.002 ; PEG-IgG 151.7 +/- 76 vs. 115.4 +/- 62 g/l, p < 0.05). However, there was no significant difference in the level of circulating LDL-ICs between the subgroup of diabetic patients with nephropathy/retinopathy and patients free of microvascular disease (Ab-oxLDL 27.7 +/- 10.4 vs. 27.1 +/- 9.3 AU, NS ; PEG-apo B 0.324 +/- 0.111 vs. 0.287 +/- 0.124 g/l, NS ; PEG-IgG 1.68 +/- 0.68 vs. 1.42 +/- 0.80 g/l, NS). There was a statistically significant positive correlation between AGE content and LDL-ICs (r = 0.35, p < 0.009). A significant but inverse correlation was recorded between triglyceride concentration and level of LDL-ICs in DM + CAD (r = - 0.32, p < 0.016) and CAD patients (r = - 0.35, p < 0.002). A highly significant negative correlation between triglycerides and circulating LDL-ICs (r = - 0.54, p < 0.039) was observed in patients with early nephropathy, but not in those with physiological proteinuria. It is known that at a high triglyceride level in type 2 diabetes, the majority of LDL are small and dense, thus being more susceptible to oxidative modification. This could be a possible mechanism explaining why more LDL-ICs, with a level inversely correlating with triglyceride concentration, are generated in diabetes. Conclusion: The increased level of circulating LDL-ICs is a risk factor for the general population, including those with diabetes. Our results suggested the contribution of LDL-ICs to the development of atherosclerosis to probably be more significant than the direct contribution of oxLDLAb itself.

Oxidized LDL; Autoantibody; Advanced Glycation End-Products; Coronary Artery Disease; Diabetic Vascular Disease

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

34 (4)

2002.

196-201-x

objavljeno

0018-5043

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost